NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-AG-16-077 from the NIH Guide for Grants and Contracts
Notice NOT-LM-17-001 from the NIH Guide for Grants and Contracts
Notice NOT-OD-17-010 from the NIH Guide for Grants and Contracts
Notice NOT-TR-17-004 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-16-017 from the NIH Guide for Grants and Contracts. Population-based Research to Optimize the Screening Process (PROSPR) is the National Cancer Institute (NCI) program to promote research aimed at evaluating and improving the cancer screening process. As a part of the reissued PROSPR program, this Funding Opportunity Announcement (FOA) solicits applications for a PROSPR U24 Coordinating Center. A companion FOA (RFA-CA-16-016) will support PROSPR UM1 Research Centers. The overall goal for the PROSPR Research Centers is to enhance understanding of the implementation and effects of screening as practiced in multiple healthcare environments in the United States.
Funding Opportunity RFA-CA-16-016 from the NIH Guide for Grants and Contracts. Population-based Research to Optimize the Screening Process (PROSPR) is the National Cancer Institute (NCI) program to promote research aimed at evaluating and improving the cancer screening process. As a part of the reissued PROSPR program, this Funding Opportunity Announcement (FOA) solicits applications for PROSPR UM1 Research Centers. A companion FOA (RFA-CA-16-017) will support a PROSPR U24 Coordinating Center. The overall goal for PROSPR Research Centers is to enhance understanding of the implementation and effects of screening as practiced in multiple, heterogeneous healthcare environments in the United States. Therefore, the research programs proposed must cover long-term observations of diverse cohorts of patients who are eligible for screening. In addition to observational research to evaluate factors that affect the quality of the screening process for the selected cancer type, these programs should also develop and pilot-test interventions aimed at improving the screening process for that cancer.
Funding Opportunity PAR-17-029 from the NIH Guide for Grants and Contracts. This FOA encourages research projects on the role of aging-related changes in systemic, peripheral, and/or non-neuronal factors individually or in combination to the pathogenesis, presentation, and/or progression of Alzheimers disease (AD). The goal of this FOA is to support innovative multidisciplinary research that will integrate the AD science with the basic biology of aging and clinical aging research. Successful studies may identify critical processes and pathophysiological pathways to inform novel prevention or intervention strategies for AD and other dementias of aging. Successful applications will likely involve a broad range of expertise including the biology of aging, geriatrics/gerontology, neurodegenerative diseases, and other clinical and translational specialties focused on systemic diseases or specific tissue/organ pathophysiology to identify interrelationships among peripheral systems and the brain.
Funding Opportunity PAS-17-028 from the NIH Guide for Grants and Contracts. This FOA encourages preclinical and clinical research to study whether, and how, different neurodegenerative disease processes interact with one another to initiate and/or hasten progression of neuropathology and dementia.
Notice NOT-NS-17-003 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-004 from the NIH Guide for Grants and Contracts
Funding Opportunity PAS-17-027 from the NIH Guide for Grants and Contracts. This FOA invites applications that address clinical and translational research gaps in the study of end-of-life care needs in order to improve quality of life at the end of life of people with Alzheimers disease and related dementias (ADRD) and their families. Research that either employs (a) secondary analysis of existing data from longitudinal cohort studies or from administrative records or (b) primary data collection for Stage I behavioral intervention development is particularly encouraged.
Funding Opportunity PAS-17-026 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose analysis of secondary data, to address clinical and translational gaps in the study of end-of-life care needs of people with Alzheimer's disease or related dementias (ADRD) and their families. Research projects involving secondary analysis of existing data from longitudinal cohort studies or from administrative records are particularly encouraged.
Funding Opportunity RFA-EB-17-001 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new and novel noninvasive human brain imaging technologies and methods that will lead to transformative advances in our understanding of the human brain. The FOA solicits unusually bold and potentially transformative approaches and supports small scale, proof of concept development based on exceptionally innovative, original and/or unconventional concepts.
Funding Opportunity RFA-EB-17-002 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support full development of entirely new or next generation noninvasive human brain imaging tools and methods that will lead to transformative advances in our understanding of the human brain. The FOA seeks innovative applications that are ready for full-scale development of breakthrough technologies with the intention of delivering working tools within the timeframe of the BRAIN Initiative (BRAIN 2025: A Scientific Vision, http://braininitiative.nih.gov/). This FOA represents the second stage of the tool/technology development effort that started with RFA-MH-14-217 and RFA-MH-15-200.
Funding Opportunity RFA-MH-17-260 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, is one of several FOAs aimed at supporting transformative discoveries that will lead to breakthroughs in understanding human brain function. Guided by the long-term scientific plan, BRAIN 2025: A Scientific Vision, this FOA specifically seeks to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements in research and development supported by the BRAIN Initiative. The hope is that efforts supported under this FOA might be both complimentary and integrative with the transformative, breakthrough discoveries being supported through the BRAIN Initiative.
Funding Opportunity RFA-AG-17-057 from the NIH Guide for Grants and Contracts. The National Institute on Aging is seeking applications to develop systems biology approaches to understand the basic biology underpinning neurodegeneration which might ultimately contribute to Alzheimer's disease or related dementias, using non-mammalian laboratory animal models. It is expected that research carried under the auspices of this FOA will lead to discovery of new mechanisms that provoke neurodegeneration and to new molecular pathways that might be involved in causing, amplifying or protecting against neurodegeneration. Applications should propose to use established non-mammalian laboratory animals which have a history of contributions to our understanding of neurobiology or aging biology.
Funding Opportunity RFA-AG-17-053 from the NIH Guide for Grants and Contracts. The goal of this FOA is to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimers disease (AD), in neural cells using human induced pluripotent stem cells or other human cell reprogramming approaches. The causal linkage of AD-associated genetic variants identified in genome-wide association studies and genome sequencing studies to molecular and biological cell phenotypes in human neural cells is expected to give greater insight into molecular targets contributing to the etiology of AD.
Notice NOT-OD-17-009 from the NIH Guide for Grants and Contracts
Notice NOT-AI-17-003 from the NIH Guide for Grants and Contracts
Notice NOT-AI-17-002 from the NIH Guide for Grants and Contracts